Northeast Financial Consultants’s Ionis Pharmaceuticals IONS Stock Holding History

Northeast Financial Consultants’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-7,740	Closed	-$277K	–	310
2023 Q1	$277K	Hold	7,740	–	–	0.02%	253
2022 Q4	$292K	Hold	7,740	–	–	0.02%	247
2022 Q3	$342K	Hold	7,740	–	–	0.03%	245
2022 Q2	$287K	Hold	7,740	–	–	0.02%	263
2022 Q1	$287K	Hold	7,740	–	–	0.02%	313
2021 Q4	$236K	Hold	7,740	–	–	0.01%	313
2021 Q3	$260K	Hold	7,740	–	–	0.02%	298
2021 Q2	$309K	Hold	7,740	–	–	0.02%	280
2021 Q1	$348K	Hold	7,740	–	–	0.03%	250
2020 Q4	$438K	Hold	7,740	–	–	0.04%	210
2020 Q3	$367K	Hold	7,740	–	–	0.03%	205
2020 Q2	$456K	Hold	7,740	–	–	0.04%	177
2020 Q1	$366K	Hold	7,740	–	–	0.04%	186
2019 Q4	$468K	Sell	7,740 -260	-3%	-$15.5K	0.04%	188
2019 Q3	$479K	Hold	8,000	–	–	0.05%	185
2019 Q2	$514K	Buy	8,000 +37	+0.5%	+$2.62K	0.05%	182
2019 Q1	$646K	Buy	+7,963	New	+$514K	0.07%	154
2018 Q3	–	Sell	-7,703	Closed	-$320K	–	159
2018 Q2	$320K	Hold	7,703	–	–	0.1%	112
2018 Q1	$339K	Hold	7,703	–	–	0.11%	111
2017 Q4	$387K	Hold	7,703	–	–	0.13%	102
2017 Q3	$391K	Hold	7,703	–	–	0.14%	103
2017 Q2	$392K	Hold	7,703	–	–	0.15%	100
2017 Q1	$310K	Hold	7,703	–	–	0.13%	114
2016 Q4	$368K	Hold	7,703	–	–	0.16%	104
2016 Q3	$282K	Buy	+7,703	New	+$241K	0.12%	122
2015 Q3	–	Sell	-3,817	Closed	-$220K	–	145
2015 Q2	$220K	Hold	3,817	–	–	0.1%	137
2015 Q1	$243K	Hold	3,817	–	–	0.11%	120
2014 Q4	$236K	Buy	+3,817	New	+$188K	0.12%	111

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

TBC

Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return

PAMS

Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Northeast Financial Consultants's IONS Position: Q2 2023 in Review

Northeast Financial Consultants sold out of Ionis Pharmaceuticals (IONS) in Q2 2023, closing a stake of 7,740 shares — an estimated $277K sold.

Northeast Financial Consultants first reported a position in IONS in Q4 2014 and held it in 28 quarters. The position peaked at $646K in Q1 2019. 304 funds tracked by Wall St. Rank hold IONS as of Q2 2023.

Northeast Financial Consultants reported no remaining Ionis Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Northeast Financial Consultants sold 7,740 Ionis Pharmaceuticals shares in Q2 2023, an estimated $277K.
Northeast Financial Consultants first reported a position in Ionis Pharmaceuticals in Q4 2014 and held it in 28 quarters.
Northeast Financial Consultants's Ionis Pharmaceuticals position peaked at $646K in Q1 2019.
304 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2023.

Based on Northeast Financial Consultants's 13F filing for Q2 2023, filed 8 Aug 2023.